ZKF-J67 (M5): Metabolic Reprogramming as a Gatekeeper for Induction/Function of Myeloid Derived Suppressor Cells in AML
FAU own research funding: EFI / IZKF / EAM ...
Start date : 01.01.2018
End date : 30.06.2021
Project details
Scientific Abstract
AML is the most common acute leukemia in adults. Emerging evidence suggests that immune alterations favor leukemogenesis and relapse. Myeloid derived suppressor cells (MDSCs) are mediators of tumor immune escape. Here, we aim to decipher the interconnection between metabolic reprogramming and MDSC abundance in AML and to unravel the role of AML-derived exosomes in this context. A better understanding is key for improving immune-based therapeutic approaches in AML.
Involved:
Contributing FAU Organisations:
Interdisziplinäres Zentrum für Klinische Forschung (IZKF)
Department of Medicine 5 – Haematology and Oncology
Medizinische Fakultät
